tetano
Editor, Senior Moderator
Clin Infect Dis
. 2021 Nov 28;ciab936.
doi: 10.1093/cid/ciab936. Online ahead of print.
Multisystem Inflammatory Syndrome in Adults after SARS-CoV-2 infection and COVID-19 vaccination
Ermias D Belay[SUP] 1 [/SUP], Shana Godfred Cato[SUP] 1 [/SUP], Agam K Rao[SUP] 1 [/SUP], Joseph Abrams[SUP] 1 [/SUP], W Wyatt Wilson[SUP] 1 2 [/SUP], Sarah Lim[SUP] 3 [/SUP], Christopher Newton-Cheh[SUP] 4 [/SUP], Michael Melgar[SUP] 1 [/SUP], Jennifer DeCuir[SUP] 1 2 [/SUP], Brandon Webb[SUP] 5 [/SUP], Paige Marquez[SUP] 1 [/SUP], John R Su[SUP] 1 [/SUP], Lu Meng[SUP] 1 [/SUP], Heather N Grome[SUP] 2 [/SUP], Elizabeth Schlaudecker[SUP] 6 [/SUP], Kawsar Talaat[SUP] 7 [/SUP], Kathryn Edwards[SUP] 8 [/SUP], Elizabeth Barnett[SUP] 9 [/SUP], Angela P Campbell[SUP] 1 [/SUP], Karen R Broder[SUP] 1 [/SUP], Sapna Bamrah Morris[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Multisystem inflammatory syndrome in adults (MIS-A) was reported in association with the COVID-19 pandemic. MIS-A was included in the list of adverse events to be monitored as part of the emergency use authorizations issued for COVID-19 vaccines.
Methods: Reports of MIS-A patients received by the Centers for Disease Control and Prevention (CDC) after COVID-19 vaccines became available were assessed. Data collected on the patients included clinical and demographic characteristics and their vaccine status. The Vaccine Adverse Events Reporting System (VAERS) was also reviewed for possible cases of MIS-A.
Results: From December 14, 2020 to April 30, 2021, 20 patients who met the case definition for MIS-A were reported to CDC. Their median age was 35 years (range, 21-66 years), and 13 (65%) were male. Overall, 16 (80%) patients had a preceding COVID-19-like illness a median of 26 days (range 11-78 days) before MIS-A onset. All 20 patients had laboratory evidence of SARS-CoV-2 infection. Seven MIS-A patients (35%) received COVID-19 vaccine a median of 10 days (range, 6-45 days) before MIS-A onset; 3 patients received a second dose of COVID-19 vaccine 4, 17, and 22 days before MIS-A onset. Patients with MIS-A predominantly had gastrointestinal and cardiac manifestations and hypotension or shock.
Conclusions: Although 7 patients were reported to have received COVID-19 vaccine, all had evidence of prior SARS-CoV-2 infection. Given the widespread use of COVID-19 vaccines, the lack of reporting of MIS-A associated with vaccination alone, without evidence of underlying SARS-CoV-2 infection, is reassuring.
Keywords: COVID-19; MIS-A; MIS-C; coronavirus; multisystem inflammatory syndrome in adults.
. 2021 Nov 28;ciab936.
doi: 10.1093/cid/ciab936. Online ahead of print.
Multisystem Inflammatory Syndrome in Adults after SARS-CoV-2 infection and COVID-19 vaccination
Ermias D Belay[SUP] 1 [/SUP], Shana Godfred Cato[SUP] 1 [/SUP], Agam K Rao[SUP] 1 [/SUP], Joseph Abrams[SUP] 1 [/SUP], W Wyatt Wilson[SUP] 1 2 [/SUP], Sarah Lim[SUP] 3 [/SUP], Christopher Newton-Cheh[SUP] 4 [/SUP], Michael Melgar[SUP] 1 [/SUP], Jennifer DeCuir[SUP] 1 2 [/SUP], Brandon Webb[SUP] 5 [/SUP], Paige Marquez[SUP] 1 [/SUP], John R Su[SUP] 1 [/SUP], Lu Meng[SUP] 1 [/SUP], Heather N Grome[SUP] 2 [/SUP], Elizabeth Schlaudecker[SUP] 6 [/SUP], Kawsar Talaat[SUP] 7 [/SUP], Kathryn Edwards[SUP] 8 [/SUP], Elizabeth Barnett[SUP] 9 [/SUP], Angela P Campbell[SUP] 1 [/SUP], Karen R Broder[SUP] 1 [/SUP], Sapna Bamrah Morris[SUP] 1 [/SUP]
Affiliations
- PMID: 34849680
- DOI: 10.1093/cid/ciab936
Abstract
Background: Multisystem inflammatory syndrome in adults (MIS-A) was reported in association with the COVID-19 pandemic. MIS-A was included in the list of adverse events to be monitored as part of the emergency use authorizations issued for COVID-19 vaccines.
Methods: Reports of MIS-A patients received by the Centers for Disease Control and Prevention (CDC) after COVID-19 vaccines became available were assessed. Data collected on the patients included clinical and demographic characteristics and their vaccine status. The Vaccine Adverse Events Reporting System (VAERS) was also reviewed for possible cases of MIS-A.
Results: From December 14, 2020 to April 30, 2021, 20 patients who met the case definition for MIS-A were reported to CDC. Their median age was 35 years (range, 21-66 years), and 13 (65%) were male. Overall, 16 (80%) patients had a preceding COVID-19-like illness a median of 26 days (range 11-78 days) before MIS-A onset. All 20 patients had laboratory evidence of SARS-CoV-2 infection. Seven MIS-A patients (35%) received COVID-19 vaccine a median of 10 days (range, 6-45 days) before MIS-A onset; 3 patients received a second dose of COVID-19 vaccine 4, 17, and 22 days before MIS-A onset. Patients with MIS-A predominantly had gastrointestinal and cardiac manifestations and hypotension or shock.
Conclusions: Although 7 patients were reported to have received COVID-19 vaccine, all had evidence of prior SARS-CoV-2 infection. Given the widespread use of COVID-19 vaccines, the lack of reporting of MIS-A associated with vaccination alone, without evidence of underlying SARS-CoV-2 infection, is reassuring.
Keywords: COVID-19; MIS-A; MIS-C; coronavirus; multisystem inflammatory syndrome in adults.
